MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Drug-radiation eliminates lung cancer

Back to lung cancer blog Blogs list Cancer blog  


Subscribe To Lung Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Drug-radiation eliminates lung cancer




Scientists at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

In a study appearing in the recent issue of Cancer Research, UT Southwestern scientists observed that if they administered BEZ235 before they damaged the DNA of tumor cells with otherwise nontoxic radiation, the drug blocked the pro-survival actions of a protein called PI3K, which normally springs into action to keep tumor cells alive while they repair DNA damage.

Scientists tested this novel therapeutic strategy in mice transplanted with NSCL cancers obtained from patients.



Drug-radiation eliminates lung cancer
Researchers, including Drs. Pier Paolo Scaglioni (right) and Georgia Konstantinidou, have eliminated non-small cell lung cancer in mice by using an investigative drug in combination with low-dose radiation.

They observed that tumors in the mice treated with BEZ235 alone were significantly smaller than those in mice not given the drug. Eventhough the tumors stopped growing, they did not die.

By contrast, tumors were completely eradicated in mice treated with a combination of BEZ235 and radiation.

"These early results suggest that the drug-radiation combination might be an effective treatment in patients with lung cancer," said Dr. Pier Paolo Scaglioni, assistant professor of internal medicine at UT Southwestern and senior author of the study.

NSCL cancer is a leading cause of cancer-related deaths worldwide. The cancer cells often harbor mutations in a gene called K-RAS. Patients with such K-RAS mutations typically are more resistant to therapy with radiation and have a poor prognosis.

K-RAS mutations lead to the activation of networks, or pathways, of several so-called signaling proteins, which in turn play key roles in the regulation of tumor growth. One of these proteins, called PI3K, is activated to keep cells alive that have sustained DNA damage.

Several components of the signaling pathways, including PI3K, have been investigated as possible anti-cancer drug targets. The investigational drug BEZ235 is currently being tested in clinical trials against PI3K and another signaling protein called mTOR.

"To date, no effective targeted treatment exists for NSCL cancer tumors that harbor K-RAS mutations," Dr. Scaglioni said.

Dr. Scaglioni and his team first tested the effectiveness of BEZ235 alone and observed that it inhibits the proliferation of both lung cancer cells cultured in vitro and the growth of lung-cancer tumors in mice.

"The results were striking, but we wanted to find a strategy to precipitate cell death of these tumors," said Dr. Georgia Konstantinidou, a postdoctoral researcher at.

UT Southwestern and the main author of the study. "We did it with radiation, which is a standard form of therapy for lung cancer".

Dr. Scaglioni's team exposed isolated cancer cells to BEZ235 followed by low doses of radiation, which induced small breaks in the DNA of the cells but otherwise would have no effect on cell survival. When this type of DNA damage occurs, cancer cells rely on the PI3K signaling pathway to survive while they repair their DNA.

"We stressed the cells in such a way that they needed this signaling pathway to survive," Dr. Scaglioni said. "Without the PI3K response, they will die".

When the scientists then treated the cells with BEZ235, which blocks PI3K, the stressed NSCL cancer cells readily underwent programmed cell death.

Dr. Scaglioni said that the next step is to use BEZ235 or similar drugs in clinical trials on NSCL cancer patients as well as other cancers, including pancreatic, colon and thyroid cancers, where the PI3K signaling pathway also plays a role.

Other UT Southwestern scientists involved in the study included Dr. Erik Bey, assistant instructor at the Harold C. Simmons Comprehensive Cancer Center, Dr. Andrea Rabellino, postdoctoral researcher in internal medicine, Dr. Katja Schuster, postdoctoral researcher in internal medicine, Dr. Adi Gazdar, professor of pathology in UT Southwestern's Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, and Dr. David Boothman, professor in the Simmons Comprehensive Cancer Center and of pharmacology and radiation oncology. Scientists from the University of Camerino in Italy and Novartis Pharma in Switzerland also participated.

The work was supported by the National Institutes of Health, American Cancer Society, Concern Foundation, Gibson Foundation, Leukemia of Texas, U.S. Department of Energy and the American Italian Cancer Foundation.


Posted by: Scott    Source




Did you know?
Scientists at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. In a study appearing in the recent issue of Cancer Research, UT Southwestern scientists observed that if they administered BEZ235 before they damaged the DNA of tumor cells with otherwise nontoxic radiation, the drug blocked the pro-survival actions of a protein called PI3K, which normally springs into action to keep tumor cells alive while they repair DNA damage.

Medicineworld.org: Drug-radiation eliminates lung cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.